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A B S T R A C T
Objective: Assessment of the role of statin therapy in the prevention of postoperative atrial ﬁbrillation
(POAF) after coronary artery bypass grafting (CABG) in patients without prior atrial ﬁbrillation.
Methods: A retrospective analysis of 206 patients, aged 57.2  7.9 years (mean  SD), who underwent
isolated CABG is carried out. All patients are divided into two groups. The ﬁrst group (nSt-patients) includes
the patients who did not receive statin therapy prior to CABG (n = 82). The second group (St-patients)
includes the patients who received statin therapy prior to CABG (n = 124). Both groups received the statin
therapy from the ﬁrst day after CABG. The risk of occurrence of POAF is evaluated using the Cox-regression
model.
Results: The rate of POAF was 25.6% in nSt-patients and 6.5% in St-patients (P = 0.020). On the 4th day
after CABG, white blood cells (WBC) count was 11.0 (9.0, 13.0)  109/mL (medians with inter-quartile
ranges) in nSt-patients and 9.0 (7.6, 10.2)  109/mL in St-patients (P < 0.001). The peak WBC numbers
occurred on the day of POAF onset. The Cox-regression analysis shows that only two factors (statin
therapy and number of grafts) had signiﬁcant inﬂuence on the POAF onset. Odds ratio of POAF event
prediction by statin therapy was 0.20 (95%CI: 0.08–0.51), P < 0.001. Each subsequent graft increased the
risk of POAF in 2.1 times.
Conclusion: Statin therapy carried out prior to the CABG is an effective approach to primary prevention of
POAF in early postoperative period. Statin therapy after CABG in nSt-patients does not give prophylactic
effect observed in St-patients.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Atrial ﬁbrillation (AF) is the most frequent postoperative
complication after cardiac surgery. Postoperative atrial ﬁbrillation
(POAF) occurs in about 65% cases.1–3 This complication leads to
prolonged hospital stay and a large economic burden.4,5
Some researchers recommend amiodarone and beta-blockers
to reduce the risk of POAF.6–8 However, it should be noted that such
preventive therapy do not seem to be safe in all patients because* Corresponding authors at: 135, Rublevskoe shosse, Moscow 121552, Russia.
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0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).of side effects of these drugs, such as hypotension and bradycardia
associated with beta-blockers and proarrhythmogenic effect of
amiodarone.9 It is assumed that one of the reasons of POAF may be
the post-operative local and systemic inﬂammation.10,11 For
example, coronary artery bypass grafting (CABG) is associated
with the increase of the inﬂammatory markers, such as C-reactive
protein, leukocytes, interleukin-6, and interleukin-8.12 Up to date,
the reason of POAF remains controversial and it is actively studied
by many researchers.13 Some anti-inﬂammatory drugs (such as
nonsteroidal anti-inﬂammatory drugs, glucocorticoids, colchicine,
and statins) have shown promising results in the prevention of
POAF.14–17
Statin therapy is recommended in patients with coronary heart
disease (CHD), but not all patients are committed to this treatment.
According to some previous studies, the statin therapy is efﬁcient open access article under the CC BY-NC-ND license (http://creativecommons.org/
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failed to demonstrate an antiarrhythmic affect of statins after
open-heart surgery.21
The aim of our study is to assess the role of statin therapy in
primary prevention of POAF in early postoperative period after
GABG.
2. Material and methods
2.1. General design of study
Design of this study was approved by the Ethics Committee
(Protocol No. 9, February 7, 2014) of the Bakoulev Center for
Cardiovascular Surgery (Moscow, Russia).
The data on the health status of all patients with CABG were
gathered retrospectively in the Department of Surgical Treatment
for Interactive Pathology, Bakoulev Scientiﬁc Center for Cardiovas-
cular Surgery (Moscow, Russia). Informed consent was obtained
from all participants.
The inclusion criteria in our study were the following:
i) CABG performed in 2013,
ii) Age from 40 to 80 years.
The patients were not included in the study if they matched the
following criteria:
i) AF prior current CABG,
ii) Concomitant surgery (e.g. CABG with valve repair/prosthesis,
CABG with aneurysmectomy, CABG with surgical correction of
ventricular septal defect, etc.),
iii) Emergency CABG,
iv) Severe renal failure (creatinine clearance calculated by the
Cockroft–Gault formula <50 mL/min),
v) Thyroid dysfunction (hyper- or hypofunction),
vi) Immunosuppressive and anti-inﬂammatory medications for
the treatment of comorbid conditions,
vii) Cancer,
viii) Organic disorders of central nervous system,
ix) Psychological disorders,
x) Left ventricle ejection fraction (LVEF) <35%,
xi) Hypo- or hyperkalemia,
xii) Treatment with amiodarone,
xiii) Other hormonal disorders.
After selection, all patients were divided into two groups:
i) The ﬁrst group was composed of patients without statin therapy
prior to CABG. We named this group as nSt-patients. Note that
all these patients began to receive the statin therapy from the
ﬁrst day after CABG.
ii) The second group was composed of patients who received the
statin therapy for at least 3 days prior to the CABG and
continuously after the operation. We named this group as St-
patients. The period of 3 days was deﬁned randomly according
to data in the literature. It is supposed that anti-inﬂammatory
effect of statins begins to appear after 3 days of starting the
therapy.22 In our study, only original atorvastatin (Pﬁzer Inc.,
USA) and rosuvastatin (AstraZeneca Pharmaceuticals LP, USA)
were used. We did not take into account the dose of statins.
We did not inﬂuence on taking any drugs before CABG, due to
the retrospective design of our study. Scarce use of statins in
ambulatory practice in patients with CHD is the challenge in many
countries, including Russia. According to population-based studiesin Russia, statins are prescribed to CHD patients much rarely than
other necessary drugs.23,24 Moreover, the use of statins is often
short. In a few months, the patients themselves stop the statin use,
motivating it by normalization of cholesterol, economic aspects,
and other reasons. This fact made it possible to carry out this
retrospective study.
2.2. Patients
In 2013, 415 CABGs were performed in Department of Surgical
Treatment for Interactive Pathology, Bakoulev Scientiﬁc Center for
Cardiovascular Surgery (Moscow, Russia). Our retrospective study
includes medical records on 206 patients with CHD (173 men and
33 women), aged 57.2  7.9 years (mean  SD), who underwent
isolated CABG in 2013. 209 patients were excluded from the study
because of fulﬁllment of the above mentioned exclusion criteria.
Clinical status of all included patients was conﬁrmed by the results of
clinical investigation.
Finally, we have identiﬁed 82 (40%) nSt-patients and 124 (60%)
St-patients.
2.3. Data collection
Clinical data including the data of physical examinations,
instrumental and laboratory investigations on all included patients
were obtained during their hospital treatment in pre-, intra-, and
postoperative periods. The source of patient’s data is a hospital
chart.
2.4. Outcomes
POAF event after CABG was the endpoint of the study. AF
episode occurred in the 7-day period after CABG and lasting
more than 5 min was deﬁned as a POAF event. In accordance to
the treatment protocol, all patients were under 24-h bedside
electrocardiography (ECG) and blood pressure (BP) monitoring for
the ﬁrst 72 h after the surgery. After 72 h after the surgery, Holter
monitoring of ECG was used every day until the day of discharge
from the hospital.
2.5. Statistical analysis
We apply the Shapiro–Wilk test to check whether the data were
approximately normally distributed. Continuous variables are
reported as medians (Me) with inter-quartile ranges (Q1, Q3) for
non-normal data or mean (M) with standard deviation (SD) for
normal data. Categorical data are presented as frequencies and
percentages. To compare the variables between the patients’
groups we use the Mann–Whitney test. The difference between the
two samples is assessed by t-test. The risk of occurrence of POAF is
evaluated using the Cox-regression model. Odds ratio is used for
the assessment of risk-factors. The obtained estimations are
considered statistically signiﬁcant if P < 0.05.
We used the software package Statistica 8.0 (StatSoft Inc., Tulsa,
Oklahoma, USA) for statistical analysis.
3. Results
The studied groups of St-patients and nSt-patients did not differ
in main anthropometric, clinical, instrumental, and laboratory
characteristics in pre-, intra-, and postoperative periods. Also, there
was no signiﬁcant difference in the length of hospital stay. The
relevant data for both groups are presented in Table 1. Signiﬁcant
differences between the groups are found in the rate of POAF and
white blood cells (WBC) in the early postoperative period (Table 1). It
should be noted that all St-patients in our study received the statin
Table 1
Anthropometric and clinical characteristics of studied patients.
Parameter nSt-patients (n = 82) St-patients (n = 124) P-level
Age, years, M  SD 57.7  8.3 56.9  7.7 0.472
Male sex, no. (%) 71 (86.6) 105 (84.7) 0.893
Body weight, kg, M  SD 82.6  12.4 82.7  11.1 0.921
BMI, kg/m2, M  SD 28.3  4.7 28.5  4.3 0.811
Smokers, no. (%) 26 (31.7) 46 (37.1) 0.223
Prior MI, no. (%) 52 (63.4) 68 (54.8) 0.225
Diabetes, no. (%) 8 (9.8) 11 (8.9) 0.911
COPD, no. (%) 2 (2.4) 5 (4.0) 0.516
Prior TIA, no. (%) 0 (0) 2 (1.6) 0.772
CRF, no. (%) 24 (29.3) 31 (25.0) 0.674
Euro SCORE II, Me (Q1, Q3) 1.87 (0.94, 2.15) 1.87 (0.94, 2.15) 0.901
Prior PCI, no. (%) 2 (2.4) 7 (5.6) 0.691
Prior statin therapy, no. (%) 0 (0) 124 (100) <0.001
Prior therapy with ACE-Is, no. (%) 81 (98.8) 120 (96.8) 0.883
Prior therapy with beta-blockers, no. (%) 81 (98.8) 121 (97.6) 0.964
LAD, cm, Me (Q1, Q3) 4.1 (3.9, 4.4) 4.1 (3.9, 4.4) 0.665
EDD, cm, Me (Q1, Q3) 5.3 (5.0, 5.7) 5.3 (4.9, 5.6) 0.293
EDV, mL, Me (Q1, Q3) 135 (122, 156) 134 (115, 154) 0.397
EFLV, %, Me (Q1, Q3) 60 (52, 64) 60 (56, 64) 0.472
Off-pump CABG, no. (%) 16 (19.5) 29 (23.4) 0.542
CPB, no. (%) 66 (80.5) 110 (88.7) 0.154
CPB time, min, Me (Q1, Q3) 112 (80, 135) 105 (78, 136) 0.951
Number of grafts, Me (Q1, Q3) 2 (2, 3) 2 (2, 3) 0.590
RCA bypass, no. (%) 45 (54.9) 71 (57.3) 0.776
Graft thrombosis, no. (%) 1 (1.2) 1 (0.8) 0.962
POAF, no. (%) 21 (25.6) 8 (6.5) 0.020
Day of AF onset, Me (Q1, Q3) 2 (2, 3), n = 21 3 (3, 4), n = 8 0.164
Preoperative WBC, 109/mL, Me (Q1, Q3) 9.8 (7.0, 10.2) 9.7 (7.3, 11.7) 0.511
WBC count on the ﬁrst day after CABG, 109/mL, Me (Q1, Q3) 10.0 (7.6, 13.0) 9.5 (7.3, 12.0) 0.290
WBC count on the 4th day after CABG, 109/mL, Me (Q1, Q3) 11.0 (9.0, 13.0) 9.0 (7.6, 10.2) <0.001
WBC count on the day of POAF onset, 109/mL, Me (Q1, Q3) 12.1 (10.0, 14.2), n = 21 14.0 (10.0, 14.5), n = 8 0.511
Number of bed-days, Me (Q1, Q3) 9 (7, 11) 9 (7, 11) 0.465
Statin therapy after CABG, no. (%) 82 (100) 124 (100) 1
Therapy with ACE-Is after CABG, no. (%) 82 (100) 124 (100) 1
Therapy with beta-blockers after CABG, no. (%) 81 (98.8) 122 (98.4) 0.931
BMI, body mass index; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure (according to exclusion criteria of our study, the
patients with moderately impaired renal function estimated by the Cockroft–Gault formula are taken into account); ACE-Is, angiotensin-converting-enzyme inhibitors; LAD,
left atrial diameter; EDD, end-diastolic dimension of left ventricle; EDV, end-diastolic volume of left ventricle; EFLV, ejection fraction of left ventricle; CPB, cardiopulmonary
bypass; RCA, right coronary artery; TIA, transient ischemic attack; WBC, white blood cells.
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this treatment. As for the nSt-patients, they did not take statins in
anamnesis.
The risk of occurrence of POAF was evaluated using the Cox-
regression model (Table 2). The indicators with high correlation
(R < 0.7) were not included together in the analysis. Such factors as
‘‘prior myocardial infarction’’, ‘‘therapy with beta-blockers’’, and
‘‘therapy with angiotensin-converting-enzyme inhibitors (ACE-
Is)’’ had high correlation (R < 0.7). Therefore, only ‘‘Prior myocar-
dial infarction’’ was included in the multiple analysis.
From the clinical variables presented in Table 2, only the statin
therapy and number of grafts are found to be statistically
meaningful for the risk of POAF after CABG. Odds ratio of POAF
event prediction by statin therapy was 0.20 (95%CI: 0.08–0.51),Table 2
Clinical variables used in the Cox-regression model for evaluation of the risk of occurr
Parameter Regression coefﬁcient (b) St
Statin therapy, yes/no 1.600 0.4
Number of grafts, no. 0.741 0.2
Therapy with beta-blockers, yes/no 1.388 1.3
EDV, mL 0.007 0.0
Diabetes 0.99 1.0
CRF 0.414 0.4
EDV, end-diastolic volume of left ventricle; CRF, chronic renal failure.
Note that the statistically signiﬁcant (P < 0.05) predictors of POAF and the ﬁrst 4 non-sign
Other indicators included in the multiple analysis (see Table 1) are not presented.P < 0.001. Each subsequent graft increased the risk of POAF
2.1 times.
4. Discussion
Despite the numerous studies on the pathophysiology of POAF
after cardiac surgery, there is still no deﬁnite answer to the
question about the reasons of POAF event in patients without prior
AF. Many factors have inﬂuence on AF, such as advanced age,
hypertension, diabetes, obesity, the expansion of the left atrium,
cardioplegia, surgical myocardial damage, oxidative stress, elec-
trolyte imbalance, etc.
We investigated the role of statin therapy in the primary
prevention of POAF after isolated CABG. We utilized WBCs as anence of POAF in patients after CABG (x2 = 28.3, P = 0.008).
andard error Risk index Exp (B) Wald test P-level
34 0.201 13.63 <0.001
97 2.099 6.23 0.013
46 0.249 1.06 0.302
07 1.007 0.976 0.323
50 0.371 0.888 0.345
64 0.660 0.79 0.372
iﬁcant factors are summarized and presented in the descending order of signiﬁcance.
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Some studies have shown that neutrophils level is more speciﬁc
independent predictor of POAF.26 It is known that due to ischemia
and reperfusion during cardioplegia (off-pump) and bypass, the
neutrophils are involved in the secretion of a wide variety of
inﬂammatory biomarkers. This study revealed the strong correla-
tion between the WBC count and risk of POAF. The rate of POAF was
signiﬁcantly higher in patients with a higher WBC count on the 4th
day after CABG (Table 1).
Understandably cardiopulmonary bypass and off-pump can
cause inﬂammation by themselves. However, the study groups did
not differ by these factors (Table 1). Therefore, in our opinion, the
impact of these factors on the outcome was equal in both studied
groups. In Cox-regression analysis, the bypass and off-pump did
not show a signiﬁcant predictive power for the risk assessment of
POAF.
Furthermore, the WBC count was maximum on the day of POAF
onset in the both study groups and the achieved maximal level was
statistically comparable in both groups (Table 1). Note that only
the patients with POAF event were taken into account, namely:
21 subjects from nSt-patients and 8 subjects from St-patients. In
these patients, the inﬂammation degree was the same regardless of
statin use. Probably it is due to genetic polymorphism affecting the
variability of anti-inﬂammatory properties of statins. For example,
a stronger lipid-lowering and non-lipid effects of atorvastatin are
known in subjects with TrpTrp genotype of polymorphic marker
Trp719Arg of KIF6 gene, AA genotype of polymorphic marker
A(290) of CYP3A4 gene, MM genotype of polymorphic marker
Met455Thr of CYP3A4 gene, GG genotype of polymorphic marker
G6986A of CYP3A5 gene, CC genotype of polymorphic marker
C(1947)A of YMGCR1 gene, etc.28,29 In the world population, the
immunity to this group of drugs varies widely depending on ethnic
features.30
Statin therapy prior to CABG and in the postoperative period is
associated with reductions in the rate of POAF and WBC count on
the 4th day in patients without prior AF (according to comparison
between nSt-patients and St-patients).
The anti-inﬂammatory effect of statins seems to be due to their
pleiotropic properties. A considerable reduction of the activity of
all inﬂammatory markers under exposure to 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) reductase inhibitors seems to be due to
their effect on neutrophils, i.e. in increase of apoptosis and
enhancement of cytokine secretion. Chello et al. reported that
using of simvastatin 40 mg/day during 7 days after surgery
reduced the peak anti-inﬂammatory markers count (interleukin
6 and interleukin 8) and WBC count.31 The anti-inﬂammatory
effect of statins begins to appear before their hypolipidemic effect.
In our study, the statin therapy started just in 3 days before CABG
led to signiﬁcant results in terms of prevention of POAF.
In our study, the Cox-regression analysis showed that only two
factors (statin therapy and number of grafts) have signiﬁcant
inﬂuence on the POAF onset. Moreover, the number of grafts
increased the risk of POAF signiﬁcantly, while the statin therapy
signiﬁcantly decreased the risk of POAF (Table 2).
Anti-inﬂammatory properties of statins have been shown in
several studies. Ikeda et al. have found that ﬂuvastatin and
simvastatin exert a considerable inhibiting effect on angiotensin 2-
induced secretion of interleukin-6 in the culture of human SMCs.
This effect was accompanied by a reduction in the level of C-
reactive protein.32 Marı`n et al. obtained similar results in a study
on 234 patients.33
Kimura et al. have shown experimentally that ﬂuvastatin can
inhibit the activities of leukotriene B4 and platelet activation
factor.34 The lipid-independent anti-inﬂammatory effect was
conﬁrmed in the experimental study performed by Scalia et al.35
who observed an inhibiting effect of simvastatin and cerivastatinon actin-mediated membrane polymerization and integrin-bind-
ing molecules of CD 11a, CD 18, and VLA-4.
The ARMYDA-3 study revealed that treatment with atorvastatin
40 mg/day, initiated 7 days before surgery, signiﬁcantly reduced
the incidence of POAF after elective cardiac surgery with
cardiopulmonary bypass. Our results agree with the main results
of Patti et al. and considerably complement them. However, there
is some difference between our results and those of Patti et al. In
our study, all nSt-patients began to receive the statin therapy from
the ﬁrst day after CABG. The criterion for inclusion in the group of
St-patients was the use of statin therapy for at least 3 days prior to
the CABG that was continued after the operation. Note that all St-
patients in our study received the statin therapy in anamnesis, but
we did not assess the regularity of this treatment. The nSt-patients
did not receive the statins in anamnesis. Thus, all patients in our
study received the statin therapy after CABG. As for Patti et al., they
compared the statin therapy with placebo. We have shown that
prescription of statins after the operation (without the preceding
statin therapy) did not give effect in primary prevention of POAF
unlike in patients receiving the regular statin therapy at least
3 days prior to the operation. This peculiarity of our study allows us
to supplement the results of the known meta-analysis carried out
by Liakopoulos et al.,37 in which the authors have shown that
evidence of supporting perioperative statin use for prevention of
AF remains inconclusive.
In a few studies, it was shown that statin therapy can lead to the
decrease in the length of hospital stay due to a reduction of the
AF.2,36 We have not seen this effect in our study. Several studies
have shown similar results.38–42 It should be noted that some of
these studies were carried out for a small number of patients.
Furthermore, different doses and types of statins were used in
these studies.
At the same time, other studies have shown signiﬁcant
association between POAF after CABG and left atrial parameters43
and between POAF and perioperative use of intra-aortic balloon
pump.44 In our study, we did not observe any such association. The
reason may be due to the design of our study mentioned in
Section 6.
5. Conclusion
Statin therapy carried out prior to the isolated CABG is an
effective approach to primary prevention of POAF in early
postoperative period. The prescription of statin therapy after
CABG in nSt-patients did not give any prophylactic beneﬁt as
observed in St-patients. The positive effect of statins may be
explained by their anti-inﬂammatory properties.
6. Limitations
There are some limitations of our study. The main being the
retrospective nature of the study, precluding any randomization
with placebo-control.
It is known that all the patients with coronary artery disease
should receive statin medication according to the clinical guide-
lines.45When a prospective randomized trial is conducted, a half of
the patients are supposed to discontinue the lipid-lowering
therapy. In our opinion, it is impossible from the ethical viewpoint
according to the contemporary recommendations. In a retrospec-
tive design of the study, we were able to enroll the patients who
were not taking statins for other reasons (social factors, economic
factors, etc.).
It should be noted that we did not analyze the reasons why the
patients did not receive the statin therapy prior to the surgery. Our
study was retrospective and to perform CABG there was no need
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lipid level control is usually within the cognizance of outpatient
cardiologist. In addition, it is known that outpatient treatment
compliance is still the unsolved problem.
In the present study, we did not evaluate the dose of statin
therapy, because of the complexity of the retrospective collection
of such data. Previously, the meta-analysis of Chen et al.46 has
shown the importance of the duration of preoperative therapy
with statins for reducing the risk of POAF, that somewhat limits the
results of our study. However, these authors found no relationship
between the dose of statins and reduced risk of POAF.
Another limitation of our study was the absence of information
about serum lipid proﬁle before the operation. Therefore, this
information was not included in the analysis. Thus, we have no
statistically signiﬁcant data to propose that the anti-ﬁbrillatory
effect of statin extends beyond their lipid lowering action.
Beta-blockers could also affect the frequency of POAF. However,
the ethical rules did not allow us to deny the patients the
medication with proven efﬁcacy. This limitation is typical for other
studies.47
It is noteworthy that all patients included in this study had
relatively high values of ejection fraction of left ventricle. It can be
explained by the fact that patients with left ventricular dysfunction
are often subjected to combined interventions (e.g., correction of
valve apparatus, etc.) that was the exclusion criterion for our study.
It is obvious that such selection of patients could inﬂuence the
study results.
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